Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.67 USD | 0.00% | -0.60% | -32.00% |
05-09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
05-09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.00% | 936M | |
+26.30% | 49.18B | |
+0.27% | 42.11B | |
+50.18% | 40.37B | |
-5.26% | 28.85B | |
+12.47% | 26.09B | |
-21.74% | 18.71B | |
+8.69% | 13.26B | |
+31.68% | 12.32B | |
-0.58% | 11.99B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Wells Fargo Initiates Viridian Therapeutics at Overweight With $46 Price Target